SCHEMBL720230

SCHEMBL720230

O=C(CCCCCCc1nc2ccc(Br)cc2[nH]1)NO

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 6/20 1.00
HDAC2 Q92769 6/20 1.00
HDAC6 Q9UBN7 5/20 1.00
HDAC3 O15379 4/20 1.00
HDAC4 P56524 4/20 1.00
HDAC7 Q8WUI4 4/20 1.00
HDAC10 Q969S8 4/20 1.00
HDAC11 Q96DB2 4/20 1.00
HDAC8 Q9BY41 4/20 1.00
HDAC9 Q9UKV0 4/20 1.00
HDAC5 Q9UQL6 4/20 1.00
MAPT P10636 4/20 0.51
PKM P14618 3/20 0.51
KDM4E B2RXH2 3/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
ALDH1A1 P00352 1/20 0.49
POLB P06746 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL719842 0.90 HDAC1 (0.81) HDAC1HDAC2HDAC6HDAC3HDAC4
SCHEMBL719635 0.83 HDAC1 (0.71) HDAC1HDAC2HDAC6HDAC3HDAC4
SCHEMBL718972 0.83 HDAC3 (0.70) HDAC1HDAC2HDAC6HDAC3HDAC4
SCHEMBL721483 0.83 HDAC3 (0.70) HDAC1HDAC2HDAC6HDAC3HDAC4
SCHEMBL16906890 0.81 HDAC1 (0.68) HDAC1HDAC2HDAC6HDAC3HDAC4
SCHEMBL38661069 0.80 APEX1 (0.70) HDAC1HDAC2HDAC6HDAC3HDAC4
SCHEMBL719373 0.80 HDAC1 (0.66) HDAC1HDAC2HDAC6HDAC3HDAC4
SCHEMBL16716725 0.79 HDAC1 (0.65) HDAC1HDAC2HDAC6HDAC3HDAC4
SCHEMBL13748129 0.79 HDAC1 (0.65) HDAC1HDAC2HDAC6HDAC3HDAC4
SCHEMBL721440 0.79 HDAC1 (0.65) HDAC1HDAC2HDAC6HDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024189607-A1 METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT DIDENKO KIRILL (MX) 2024-09-19 WO disclosed
US-20230321130-A1 Senolytic Compositions and Uses Thereof Rubedo Life Sciences, Inc. 2023-10-12 US disclosed
US-20230137021-A1 Drug Conjugates of Sugar Derivatives and Uses Thereof as Senolytic Agents Rubedo Life Sciences, Inc. 2023-05-04 US disclosed
US-20230137021-A1 Drug Conjugates of Sugar Derivatives and Uses Thereof as Senolytic Agents Rubedo Life Sciences, Inc. 2023-05-04 US disclosed
US-9381196-B2 Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) 2016-07-05 US disclosed
US-20150196559-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HYDROXAMIC ACID DERIVATIVES THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) 2015-07-16 US disclosed
US-8987468-B2 Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) 2015-03-24 US disclosed
US-20120053188-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HYDROXAMIC ACID DERIVATIVES THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE(TGEN (US) 2012-03-01 US disclosed
WO-2009100045-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HYDROXAMIC ACID DERIVATIVES TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) 2009-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053188-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HYDROXAMIC ACID DERIVATIVES HDAC5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HDAC4 HDAC1 11/4885HDAC2 15/4885HDAC6 5/4885
US-20230137021-A1 Drug Conjugates of Sugar Derivatives and Uses Thereof as Senolytic Agents AGER, SENP6, SENP3 HDAC1 861/4885HDAC2 1138/4885HDAC6 275/4885
US-20230321130-A1 Senolytic Compositions and Uses Thereof SENP3, SENP6, SENP1 HDAC1 1056/4885HDAC2 1020/4885HDAC6 514/4885
US-20150196559-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HYDROXAMIC ACID DERIVATIVES HDAC5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HDAC4 HDAC1 11/4885HDAC2 15/4885HDAC6 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.